|
1
|
Ferrara JL, Levine JE, Reddy P and Holler
E: Graft-versus-host disease. Lancet. 373:1550–1561. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bacigalupo A: Management of acute
graft-versus-host disease. Br J Haematol. 137:87–98. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
MacMillan ML, Weisdorf DJ, Wagner JE,
DeFor TE, Burns LJ, Ramsay NK, Davies SM and Blazar BR: Response of
443 patients to steroids as primary therapy for acute
graft-versus-host disease: Comparison of grading systems. Biol
Blood Marrow Transplant. 8:387–394. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Deeg HJ: How I treat refractory acute
GVHD. Blood. 109:4119–4126. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Perez L, Anasetti C and Pidala J: Have we
improved in preventing and treating acute graft-versus-host
disease? Curr Opin Hematol. 18:408–413. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Garnett C, Apperley JF and Pavlů J:
Treatment and management of graft-versus-host disease: Improving
response and survival. Ther Adv Hematol. 4:366–378. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang Y, Chen X, Cao W and Shi Y:
Plasticity of mesenchymal stem cells in immunomodulation:
Pathological and therapeutic implications. Nat Immunol.
15:1009–1016. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fajardo-Orduña GR, Mayani H and Montesinos
JJ: Hematopoietic support capacity of mesenchymal stem cells:
Biology and clinical potential. Arch Med Res. 46:589–596. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dotoli GM, De Santis GC, Orellana MD, de
Lima Prata K, Caruso SR, Fernandes TR, Rensi Colturato VA, Kondo
AT, Hamerschlak N, Simões BP and Covas DT: Mesenchymal stromal cell
infusion to treat steroid-refractory acute GvHD III/IV after
hematopoietic stem cell transplantation. Bone Marrow Transplant.
52:859–862. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Muroi K, Miyamura K, Okada M, Yamashita T,
Murata M, Ishikawa T, Uike N, Hidaka M, Kobayashi R, Imamura M, et
al: Bone marrow-derived mesenchymal stem cells (JR-031) for
steroid-refractory grade III or IV acute graft-versus-host disease:
A phase II/III study. Int J Hematol. 103:243–250. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cho KA, Park M, Kim YH, Ryu KH and Woo SY:
Mesenchymal stem cells inhibit RANK-RANKL interactions between
osteoclasts and Th17 cells via osteoprotegerin activity.
Oncotarget. 8:83419–83431. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cho KA, Lee JK, Kim YH, Park M, Woo SY and
Ryu KH: Mesenchymal stem cells ameliorate B-cell-mediated immune
responses and increase IL-10-expressing regulatory B cells in an
EBI3-dependent manner. Cell Mol Immunol. Jan 2–2017;(Epub ahead of
print).
|
|
13
|
Cho KA, Park M, Kim YH, Woo SY and Ryu KH:
Conditioned media from human palatine tonsil mesenchymal stem cells
regulates the interaction between myotubes and fibroblasts by
IL-1Ra activity. J Cell Mol Med. 21:130–141. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ryu KH, Cho KA, Park HS, Kim JY, Woo SY,
Jo I, Choi YH, Park YM, Jung SC, Chung SM, et al: Tonsil-derived
mesenchymal stromal cells: Evaluation of biologic, immunologic and
genetic factors for successful banking. Cytotherapy. 14:1193–1202.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cantinieaux D, Quertainmont R, Blacher S,
Rossi L, Wanet T, Noël A, Brook G, Schoenen J and Franzen R:
Conditioned medium from bone marrow-derived mesenchymal stem cells
improves recovery after spinal cord injury in rats: An original
strategy to avoid cell transplantation. PLoS One. 8:e695152013.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gehmert S, Wenzel C, Loibl M, Brockhoff G,
Huber M, Krutsch W, Nerlich M, Gosau M, Klein S, Schreml S, et al:
Adipose tissue-derived stem cell secreted IGF-1 protects myoblasts
from the negative effect of myostatin. Biomed Res Int.
2014:1290482014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sadeghi B, Aghdami N, Hassan Z,
Forouzanfar M, Rozell B, Abedi-Valugerdi M and Hassan M: GVHD after
chemotherapy conditioning in allogeneic transplanted mice. Bone
Marrow Transplant. 42:807–818. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cho KA, Woo SY, Park YS, Park MH and Ryu
KH: Macrophage inflammatory protein-2 (MIP-2)/CXCR2 blockade
attenuates acute graft-versus-host disease while preserving
graft-versus-leukemia activity. Biochem Biophys Res Commun.
426:558–564. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Joo SY, Cho KA, Jung YJ, Kim HS, Park SY,
Choi YB, Hong KM, Woo SY, Seoh JY and Ryu KH: Bioimaging for the
monitoring of the in vivo distribution of infused mesenchymal stem
cells in a mouse model of the graft-versus-host reaction. Cell Biol
Int. 35:417–421. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Joo SY, Cho KA, Jung YJ, Kim HS, Park SY,
Choi YB, Hong KM, Woo SY, Seoh JY, Cho SJ and Ryu KH: Mesenchymal
stromal cells inhibit graft-versus-host disease of mice in a
dose-dependent manner. Cytotherapy. 12:361–370. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Dyer DP, Thomson JM, Hermant A, Jowitt TA,
Handel TM, Proudfoot AE, Day AJ and Milner CM: TSG-6 inhibits
neutrophil migration via direct interaction with the chemokine
CXCL8. J Immunol. 192:2177–2185. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Dyer DP, Salanga CL, Johns SC, Valdambrini
E, Fuster MM, Milner CM, Day AJ and Handel TM: The
anti-inflammatory protein TSG-6 regulates chemokine function by
inhibiting chemokine/glycosaminoglycan interactions. J Biol Chem.
291:12627–12640. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kebriaei P, Isola L, Bahceci E, Holland K,
Rowley S, McGuirk J, Devetten M, Jansen J, Herzig R, Schuster M, et
al: Adult human mesenchymal stem cells added to corticosteroid
therapy for the treatment of acute graft-versus-host disease. Biol
Blood Marrow Transplant. 15:804–811. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Arima N, Nakamura F, Fukunaga A, Hirata H,
Machida H, Kouno S and Ohgushi H: Single intra-arterial injection
of mesenchymal stromal cells for treatment of steroid-refractory
acute graft-versus-host disease: A pilot study. Cytotherapy.
12:265–268. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wysocki CA, Panoskaltsis-Mortari A, Blazar
BR and Serody JS: Leukocyte migration and graft-versus-host
disease. Blood. 105:4191–4199. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kim JY, Park M, Kim YH, Ryu KH, Lee KH,
Cho KA and Woo SY: Tonsil-derived mesenchymal stem cells (T-MSCs)
prevent Th17-mediated autoimmune response via regulation of the
programmed death-1/programmed death ligand-1 (PD-1/PD-L1) pathway.
J Tissue Eng Regen Med. 12:e1022–e1033. 2018. View Article : Google Scholar : PubMed/NCBI
|
